Targeting a deep brain hub without incisions
How the randomized crossover trial worked
The trial was registered on ClinicalTrials.gov in November 2022, with the full protocol and analysis plan published there alongside code. It enrolled 11 outpatients aged 18 to 55 with schizophrenia or schizoaffective disorder and at least moderate symptoms between May 2023 and January 2024; one participant withdrew after a brain scan, leaving 10 who completed the study.
Moderate reductions in delusions and an unexpected delay
Across post‑baseline assessments, delusion scores fell by an average of 1.2 points after active stimulation versus a 0.4‑point rise after sham. In the primary model, active ultrasound yielded an estimated 1.56‑point greater reduction than sham, a moderate effect size (Cohen’s d = 0.68). Individual responses varied widely across the two‑week crossover sequence.
One intriguing finding was that the delusion‑reduction effect appeared to persist and even widen from day one to day seven after stimulation, though this exploratory pattern did not reach statistical significance after correcting for multiple tests. The researchers suggested that pulsed ultrasound might trigger lasting neuroplastic changes in glutamate signaling within the right globus pallidus interna and its connected cortical loop, gradually consolidating to reduce aberrant salience. The authors caution that a single 10‑minute session in 10 participants over one week constitutes a preliminary proof‑of‑concept. While the observed delusion effect was comparable in magnitude to effects seen in some antipsychotic trials, the measure used tracked moment‑to‑moment fluctuations rather than full clinical recovery. They stress that the approach is not a cure and should not be conflated with existing clinical therapies.Caveats and next steps for ultrasound research
